The Future of Vaccines: How to Harness the Full Potential of IVT-RNA

How the market is growing globally, the diseases that IVT-RNA vaccines can protect against, how the market is growing, and the indicators of future growth.

22

January

  • 3PM GMT
  • Free

Why attend?

IVT-RNA is set to be a vital tool in future vaccine production, possessing the versatility to be quickly adapted to meet changing requirements such as new variants of viruses. The effectiveness of IVT-RNA was demonstrated in the success of the Covid-19 vaccines, which were built on decades of research.

However, the increasing demands for vaccines produced at scale make reliable quality controls an essential requirement of manufacturing.

In this webinar, we will discuss the capabilities of IVT-RNA vaccines, the diseases that could be protected against, the clinical trials underway showing the most promise, how the market is growing globally, and the indicators of future growth according to GlobalData analysts.

Agilent will also provide expert insight on the best ways to implement quality control measures in IVT-RNA vaccine production and the key devices that can enable this. The company is an internationally respected provider of advanced testing instruments for use in life sciences.

In this webinar, we will explore:

– The potential uses cases for IVT-RNA vaccines

– How IVT-RNA could bring down the costs of producing vaccines

– The advantages of IVT-RNA over other forms of biopharma production

– How to ensure quality control across vaccine manufacturing

Speakers

Select a speaker to learn more

Back
Dr. Leslie Friedmann
Product Manager Parallel Capillary Electrophoresis (CE) instruments, Waldbronn
Next speaker
Back
Nancy Jaser, PharmD/MBA
Senior Analyst , GlobalData
Next speaker
Back
Professor Harris Makatsoris
Professor Of Manufacturing Systems in the Department of Engineering at King’s College

Harris is Professor Of Manufacturing Systems in the Department of Engineering at King’s College London. He has a process engineering background with 20-years work experience in both industry and academia. In all his past and present roles, he is managing interdisciplinary projects that require integration and coordination. Harris is an expert in continuous RNA manufacturing. His work is focusing on addressing the challenges in the rapid design, development and scalable manufacture of RNA and other nucleic acids and has pioneered the application of flow technologies in RNA manufacture, of various types. His research has attracted over £25m and he is currently leading a unique multi-disciplinary, multi-million pound programme comprising both industry and academia, building the Biofoundry-in-a-Box (BiaB). The BiaB is a unique portable, multi purpose RNA microfactory designed for the rapid design and deployment of a range of therapeutics and vaccines, with Low and Middle Income Countries in mind. He has several patents in his name in the space of RNA manufacture and continuous bioprocessing and is highly experienced in technology transfer to industry through a variety of commercial routes.

Next speaker

Enquiry